Skip to main content
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. — Investor Relations & Filings

Ticker · PLX ISIN · US74365A3095 LEI · 549300SDVB3GP4XDFM60 US Manufacturing
Open in API
Filings indexed 950 across all filing types
Latest filing 2023-02-24 Regulatory Filings
Country US United States of America
Listing US PLX

About Protalix BioTherapeutics, Inc.

https://protalix.com/

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins. The company's unique selling point is its proprietary ProCellEx® platform, a plant cell-based protein expression system used to manufacture complex proteins. This technology supports the development of treatments for rare and orphan diseases. Protalix has successfully brought enzyme replacement therapies to market and maintains a pipeline of product candidates targeting conditions with high unmet medical needs. The company's capabilities cover the entire process from protein candidate selection and genetic engineering of plant cells through preclinical and clinical development to commercial-scale production and marketing.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes an announcement about the European Medicines Agency's positive opinion recommending marketing authorization for a drug, and it references an attached press release. The document is short (3470 characters) and primarily serves as an announcement of an event rather than a detailed financial report or other specific filing type. It does not contain financial statements or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-02-24 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-01-05 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. It includes a press release discussing regulatory and clinical developments, but does not contain detailed financial statements or comprehensive financial data. The document length is 3767 characters, which is relatively short and mainly serves as an announcement rather than a full report. It references a press release as an exhibit and explicitly states that the information is furnished and not filed, indicating it is an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-01-03 English
SC 13G/A
Major Shareholding Notification
2023-01-03 English
8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content specifically announces the company's decision to voluntarily delist its common stock from the Tel Aviv Stock Exchange (TASE), including the delisting date and last trading date. This is a clear official notice of a delisting event. The document is about a specific event (delisting) rather than a financial report or earnings release. Therefore, the appropriate classification is Delisting Announcement (DLST). The document length is 5655 characters, which is sufficient to contain substantive information about the delisting event, not just a brief announcement or a report publication notice.
2022-12-27 English
8-K
Delisting Announcement Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 21, 2022. The key content is an announcement that Protalix BioTherapeutics, Inc. has decided to voluntarily delist its common stock from the Tel Aviv Stock Exchange (TASE). The document includes a press release about the delisting and states that trading on the NYSE American will be unaffected. There are no financial statements or detailed financial data presented, only an event announcement. The primary subject is the delisting of the company's stock from an exchange, which matches the definition of a Delisting Announcement (DLST). The document length is 3510 characters, which is short and consistent with an announcement rather than a full report. Therefore, the correct classification is DLST with high confidence.
2022-12-21 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.